4-(2-hydroxy-ethylamino)-2-methylsulfanyl-6-(4-phenyl-piperidin-1-yl)-pyrimidine-5-carbonitrile | 478180-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-hydroxy-ethylamino)-2-methylsulfanyl-6-(4-phenyl-piperidin-1-yl)-pyrimidine-5-carbonitrile
• 英文别名: 4-(2-hydroxyethylamino)-2-methylsulfanyl-6-(4-phenylpiperidin-1-yl)pyrimidine-5-carbonitrile
• CAS: 478180-40-4
• 化学式: C₁₉H₂₃N₅OS
• 分子量: 369.491
• InChiKey: HDJGFMHEEFZSDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-苯基哌啶 、 N,N-二异丙基乙胺 、 6-chloro-4-(2-hydroxyethylamino)-2-methylthiopyrimidine-5-carbonitrile 在 silica gel 、 二氯甲烷 、 甲醇 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以yielding 490 mg (1.33 mmol, 70% of theory) of the 4-(2-hydroxy-ethylamino)-2-methylsulfanyl-6-(4-phenyl-piperidin-1-yl)-pyrimidine-5-carbonitrile as an amorphous, white solid的产率得到4-(2-hydroxy-ethylamino)-2-methylsulfanyl-6-(4-phenyl-piperidin-1-yl)-pyrimidine-5-carbonitrile
  参考文献：
  名称：

  Pyrimidine, pyrazine and triazane derivatives

  摘要：

  本发明是一种嘧啶、三嗪或吡嗪衍生物，其化学式为或其药学上可接受的盐，其中R1、R2、R3、R4、X、Y和Z如规范中所定义。本发明是一种含有化合物1的有效量的药物组合物，以及其制备和通过给予化合物1的治疗、控制或预防急性和/或慢性神经疾病的方法。

  公开号：

  US06673795B2

文献信息

• Pyrimidine, pyrazine and triazine derivatives
  申请人：——

  公开号：US20030060466A1

  公开（公告）日：2003-03-27

  The present invention is a pyrimidine, triazine or pyrazine derivative of the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined in the specification. The invention is a pharmaceutical composition containing an effective amount of the compound of formula 1, its preparation and to a method of treatment, control or prevention of acute and/or chronic neurological disorders by administering a therapeutically effective amount of a compound of formula 1.

  本发明是一种嘧啶、三嗪或吡嗪衍生物的化学式1或其药用盐，其中R1、R2、R3、R4、X、Y和Z如规范中定义。该发明是一种含有化学式1化合物的有效量的药物组合物，以及其制备方法和通过给予化学式1化合物的治疗有效量来治疗、控制或预防急性和/或慢性神经系统疾病的方法。
• PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1397351B1

  公开（公告）日：2009-11-11
• US6673795B2
  申请人：——

  公开号：US6673795B2

  公开（公告）日：2004-01-06
• [EN] PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS<br/>[FR] DERIVES DE PYRIMIDINE, TRIAZINE ET PYRAZINE, RECEPTEURS DU GLUTAMATE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002098864A1

  公开（公告）日：2002-12-12

  The present invention relates to pyrimidine, triazine and pyrazine derivatives of the general formula (I), wherein R?1, R2, R3, R4¿, X, Y and Z have the significances given in the specification ,as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing these compounds, their preparation and to their use for the control or prevention of acute and/or chronic neurological disorders.
• Pyrimidine, pyrazine and triazane derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06673795B2

  公开（公告）日：2004-01-06

  The present invention is a pyrimidine, triazine or pyrazine derivative of the formula or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, X, Y and Z are as defined in the specification. The invention is a pharmaceutical composition containing an effective amount of the compound of formula 1, its preparation and to a method of treatment, control or prevention of acute and/or chronic neurological disorders by administering a therapeutically effective amount of a compound of formula 1.

  本发明是一种嘧啶、三嗪或吡嗪衍生物，其化学式为或其药学上可接受的盐，其中R1、R2、R3、R4、X、Y和Z如规范中所定义。本发明是一种含有化合物1的有效量的药物组合物，以及其制备和通过给予化合物1的治疗、控制或预防急性和/或慢性神经疾病的方法。